Table 4.

Overview of the embryologic outcome from cycles after SARS-CoV-2 infection from the same patient.

Patient	Age (y)	Time since the previous cycle (d)	ART	Treatment protocol	No. of COC	No. of MII (% per COC)	No. of 2PN (% per MII)	No. of embryos of quality 1 and 2 on day 3 (% per 2PN)	No. of embryos of quality 1 and 2 on day 5 (% per 2PN)	Treatment outcome
1	39	307	ICSI	Antagonist	5	5 (100.0)	4 (80.0)	3 (75.0)	1 (33.3)b	Embryo transfer day 3; freezing day 5
2	37	84	ICSI	Antagonist	10	6 (60.0)	5 (83.3)	3 (60.0)	1 (25.0)b	Embryo transfer day 3; freezing day 5/6
3	38	127	ICSI	Modified natural cycle	1	1 (100.0)	1 (100.0)	1 (100.0)	N/A	Embryo transfer day 3
3	39	203	ICSI	Modified natural cycle	4	2 (50.0)	1 (50.0)	1 (100.0)	N/A	Embryo transfer day 3
3	39	308	ICSI	Modified natural cycle	4	2 (50.0)	2 (100.0)	2 (100.0)	N/A	Embryo transfer day 3
4	35	136	ICSI	Antagonist	10	9 (90.0)	4 (44.4)	0	N/A	Embryo transfer day 3
7	40	73	ICSI	Agonist	3	3 (100.0)	3 (100.0)	3 (100.0)	1 (33.3)	Insufficient quality for trophectoderm biopsy
11	34	40	ICSI	Modified natural cycle	1	1 (100.0)	1 (100.0)	1 (100.0)	N/A	Embryo transfer day 3
13	31	111	ICSI	Antagonist	16	13 (81.3)	7 (53.8)	5 (71.4)	N/A	Embryo transfer day 3; freezing day 3
15	38	62	IVF	Agonist	10	N/A	5 (50.0)a	1 (20.0)	N/A	Embryo transfer day 3
16	31	55	IVF	Antagonist	6	N/A	5 (83.3)a	3 (60.0)	1 (25.0)b	Embryo transfer day 3; freezing day 5

Note: ART = assisted reproductive technology; COC = cumulus-oocyte complex; ICSI = intracytoplasmic sperm injection; IVF = in vitro fertilization; MII = metaphase II oocytes; N/A = not applicable; 2PN = fertilized oocyte.

^aCalculated per number of COC.

^bCalculated per number of 2PN minus 1embryo transferred on day 3.